|행 사 명||제1회 감염병연구기관 국제심포지엄|
|개최일정||2023년 2월 22일(수) ~ 23(목), 2일간|
|진행일정||Day1 (2. 22) 종일: 미국 NIAID
Day2 (2. 23) 1부: 싱가포르 NCID / 2부: 덴마크 SSI
|장 소||메종 글래드 제주(크리스탈홀, 본관 2층)|
|참석대상||국내‧외 감염병 국제협력 관계자 및 전문가 등|
Introduction of the institute
National Institute of Allergy and Infectious Diseases (NIAID)
The National Institute of Allergy and Infectious Diseases (NIAID) is one of the 27 Institutes and Centers of the U.S. National Institutes of Health (NIH), U.S. Department of Health and Human Services. It was originally established in 1948 as The National Microbiological Institute, which became NIAID in 1955. NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. This research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. NIAID is composed of seven research divisions: The Division of AIDS (DAIDS); the Division of Allergy, Immunology, and Transplantation (DAIT); the Division of Clinical Research (DCR); the Division of Extramural Activities (DEA); the Division of Intramural Research (DIR); the Division of Microbiology and Infectious Diseases (DMID); and the Dale and Betty Bumpers Vaccine Research Center (VRC). DAIDS, DAIT, and DMID direct and manage grants, contracts, and cooperative agreements that support research at external academic and research institutions (known as extramural research), while DCR, DIR, and the VRC conduct studies and clinical investigations within NIAID laboratories (known as intramural research).
Following Dr. Anthony Fauci’s retirement as the Director of NIAID on December 31, 2022, Dr. Hugh Auchincloss has assumed the role of Acting Director of NIAID. He has served as NIAID’s Principal Deputy Director since joining NIH in 2006 and has played a key role in research planning and implementation activities, including helping to prepare and support a strategic vision for NIAID, and contributing to the management of NIAID’s extensive portfolio of basic, clinical, and applied research and product development activities.
Statens Serum Institute (SSI)
Statens Serum Institut (SSI) is a public health preparedness and research institute under the auspices of the Danish Ministry of Interior and Health. The Institute’s main duty is to ensure preparedness against infectious diseases and biological threats as well as control of congenital disorders. Its mission is to strengthen health through disease control and research. As such, all of SSI’s activities are grounded in research and each year, the institute publishes around 400 scientific articles. Established in 1902 to secure the production and supply of anti-diphtheria serum to Danish patients, SSI has been incremental in fighting infectious diseases in Denmark for 120 years.
National Centre for Infectious Diseases (NCID)
The National Centre for Infectious Diseases (NCID) is a purpose-built facility designed to strengthen Singapore’s capabilities in infectious disease management and prevention. NCID houses clinical services, public health, research, training and education and community engagement functions under one overarching structure. In addition to the clinical treatment of infectious diseases and outbreak management, the expanded roles and functional units of NCID include the National Public Health and Epidemiology Unit, the National Public Health Laboratory, the Infectious Disease Research and Training Office, the Antimicrobial Resistance Coordinating Office, and the National Public Health programmes for HIV and Tuberculosis. Benchmarked to international standards and best practices, NCID will enhance Singapore’s ability to effectively manage infectious diseases.
Visit www.ncid.sg for more information.
Photo credit: National Centre for Infectious Diseases